Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, which ...
Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the recipient of unusually large options trading on Wednesday.Stock traders bought 21,787 call options on the company. This is an increase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback